医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Hold a Conference Call on Nov 9, 2015 at 4.00 PM IST / 5.30 AM EST

2015年11月07日 AM02:21
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will hold a Conference Call on November 9, 2015 to clarify investors’ queries on the Warning Letter issued by the US FDA dated November 05, 2015.

Audio Webcast

The audio webcast of the call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the call, through Nov 13, 2015. For play back dial in phone No: 022 3065 2322, 022 61813322 and ID: 375#.

Transcript

The transcript of the call will also be available on the Company’s website.

Conference Dial-In Numbers
Primary Number:   +91 22 3960 0616
Secondary Number:   +91 22 6746 5826
The numbers listed above are universally accessible from all networks and all countries.
Local Access Number:   6000 1221
Available in – - Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada

Accessible from all major carriers except BSNL/MTNL.

3940 3977

Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune

Accessible from all carriers.

International Toll Free Number:  

USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151106005825/en/

CONTACT

Dr. Reddy’s Laboratories
INVESTOR RELATIONS
Kedar
Upadhye, +91-40-66834297
kedaru@drreddys.com
or
MEDIA
RELATIONS

Calvin Printer, +91-40-49002121
calvinprinter@drreddys.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表